Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(2.84)
# 1,872
Out of 4,996 analysts
77
Total ratings
37.04%
Success rate
1.24%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GNFT Genfit | Maintains: Buy | $9 → $7 | $3.45 | +102.90% | 2 | Sep 24, 2025 | |
| RNTX Rein Therapeutics | Initiates: Buy | $10 | $1.18 | +747.46% | 1 | Sep 22, 2025 | |
| MNKD MannKind | Reiterates: Buy | $11 | $5.53 | +98.92% | 5 | Sep 18, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $93 → $121 | $93.05 | +30.04% | 6 | Sep 17, 2025 | |
| VALN Valneva SE | Reiterates: Buy | $18 | $9.71 | +85.38% | 2 | Aug 25, 2025 | |
| DERM Journey Medical | Initiates: Buy | $13 | $7.04 | +84.69% | 2 | Aug 25, 2025 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $3.01 | +298.67% | 2 | Aug 21, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Reiterates: Buy | $12 | $5.74 | +109.06% | 3 | Aug 20, 2025 | |
| PYPD PolyPid | Reiterates: Buy | $13 | $3.33 | +290.39% | 4 | Aug 13, 2025 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $7 | $1.58 | +343.04% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $8.18 | +22.25% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $44 | $34.41 | +27.87% | 6 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $11.30 | +50.44% | 3 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $29 | $7.34 | +295.10% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $23.92 | +17.06% | 1 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $7.90 | +153.16% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $9.77 | +166.12% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.21 | +395.87% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $5 | $2.00 | +150.00% | 2 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.08 | +733.33% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.77 | +139.45% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.27 | +293.70% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.46 | +101.79% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.34 | +2,224.91% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $8.91 | +79.57% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.48 | +1,983.33% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $29.21 | +1,457.69% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $31.85 | +85.24% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $127.00 | +41.73% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $3.73 | +5,798.12% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $27.89 | +14.74% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.84 | +1,195,552.17% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $15.00 | +233.33% | 1 | Jul 12, 2018 |
Genfit
Sep 24, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $3.45
Upside: +102.90%
Rein Therapeutics
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.18
Upside: +747.46%
MannKind
Sep 18, 2025
Reiterates: Buy
Price Target: $11
Current: $5.53
Upside: +98.92%
ANI Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $93.05
Upside: +30.04%
Valneva SE
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $9.71
Upside: +85.38%
Journey Medical
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $7.04
Upside: +84.69%
Achieve Life Sciences
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $3.01
Upside: +298.67%
Eupraxia Pharmaceuticals
Aug 20, 2025
Reiterates: Buy
Price Target: $12
Current: $5.74
Upside: +109.06%
PolyPid
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $3.33
Upside: +290.39%
Connect Biopharma Holdings
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $1.58
Upside: +343.04%
Aug 12, 2025
Assumes: Buy
Price Target: $10
Current: $8.18
Upside: +22.25%
Aug 11, 2025
Assumes: Buy
Price Target: $44
Current: $34.41
Upside: +27.87%
Aug 8, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $11.30
Upside: +50.44%
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $7.34
Upside: +295.10%
Aug 6, 2025
Initiates: Buy
Price Target: $28
Current: $23.92
Upside: +17.06%
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $7.90
Upside: +153.16%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $9.77
Upside: +166.12%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.21
Upside: +395.87%
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $2.00
Upside: +150.00%
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $1.08
Upside: +733.33%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $8.77
Upside: +139.45%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.27
Upside: +293.70%
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $4.46
Upside: +101.79%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.34
Upside: +2,224.91%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $8.91
Upside: +79.57%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $0.48
Upside: +1,983.33%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $29.21
Upside: +1,457.69%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $31.85
Upside: +85.24%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $127.00
Upside: +41.73%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $3.73
Upside: +5,798.12%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $27.89
Upside: +14.74%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.84
Upside: +1,195,552.17%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $15.00
Upside: +233.33%